Although the use of expressed antiviral miRNA sequences to treat viral infections is encouraging, eventual therapeutic application will be dependent on rigorously proving their safety, efficient delivery to target tissues and uncomplicated large scale preparation of vector formulations.
Fosfomycin tromethamine is an oral formulation approved for the treatment of uncomplicated urinary tract infection caused by multidrug-resistant (MDR) bacteria.
In Uganda the current and previous national malaria treatment policy recommends quinine, given in its tablet formulation, as the second line treatment for uncomplicated malaria.
In this open, non-comparative study in Cameroonian children with uncomplicated falciparum malaria, the safety and efficacy of this formulation was tested, with a particular emphasis on the risk of neuropsychiatric adverse events (AEs).
The assessment of the safety and efficacy of a new pediatric granule formulation of artesunate-mefloquine in the treatment of uncomplicated falciparum malaria in African children weighing 10 20 kg was the main purpose of this study.
Against this background, the safety and efficacy of the new granule formulation of artesunate-mefloquine was investigated in young African children with uncomplicated P. falciparum malaria.
This was an open, randomized, parallel study of piperaquine pharmacokinetics when administered as a fixed oral formulation once daily for 3 days with and without concomitant fat to patients with uncomplicated P. falciparum malaria in Thailand.
To compare the efficacy and safety of a single 2.0-g dose of a novel azithromycin microsphere formulation with that of 10 days of levofloxacin, 500 mg/d, when used to treat adults with uncomplicated acute bacterial maxillary sinusitis (ABS).
We therefore conducted a phase III, randomized, non-inferiority trial of this new formulation to assess the efficacy and safety in comparison with artesunate-mefloquine (AM) in patients with acute, uncomplicated P. falciparum malaria in Laos.
It is available in oral and intravenous (IV) formulations and has been approved by the Food and Drug Administration for the treatment of numerous infections, including cSSIs or uncomplicated SSIs, without concomitant osteomyelitis, caused by S. aureus [ 39].
